ライフサイエンスコーパス: vasoactive intestinal peptide

1 GM-CSF, and IL-4 as well as the neuropeptide vasoactive intestinal peptide.

2 rtion of the OFQ-IR neurons was positive for vasoactive intestinal peptide.

3 hat bound both PACAP and the related peptide vasoactive intestinal peptide.

4 tistatin and calretinin, cholecystokinin, or vasoactive intestinal peptide.

5 dibutyryl cAMP, cholera toxin, forskolin, or vasoactive intestinal peptide.

6 id delivery and other issues associated with vasoactive intestinal peptide.

7 de-2, gastric-inhibitory peptide, and prepro-vasoactive intestinal peptide.

8 MP-generating agonists such as forskolin and vasoactive intestinal peptide.

9 hrine (10 microm each) were ineffective, but vasoactive intestinal peptide (1 microm) and forskolin (

10 hereby these responses may be downregulated: vasoactive intestinal peptide (1 microM) elevates cyclic

11 0(-8) M and 15 x 10(-9) M, respectively, for vasoactive intestinal peptide 28.

12 the hypersecretion of insulin (5 patients), vasoactive intestinal peptide (5 patients), gastrin (2 p

13 are predominantly noncholinergic and contain vasoactive intestinal peptide, a marker of secretomotor

14 and duodenal acidity, and overexpressed the vasoactive intestinal peptide-a myorelaxant factor for t

15 n with cholecystokinin (CCK), carbachol, and vasoactive intestinal peptide all induced Rap1 activatio

16 The circadian synchronizer vasoactive intestinal peptide also stimulates ILC2 cells

17 Treatment with vasoactive intestinal peptide, an anti-inflammatory neur

18 hPAC1-R(S) selectivity for PACAP versus the vasoactive intestinal peptide and also differentiate PAC

19 we found that two Gs-coupled receptors (the vasoactive intestinal peptide and beta-adrenergic recept

20 Under in vitro stimulation with vasoactive intestinal peptide and CD40L, IGIP mRNA expre

21 The DeltaF508 mice overexpressed vasoactive intestinal peptide and had defects in gallbla

22 hate and Na nitroprusside), or both kinases (vasoactive intestinal peptide and isoproterenol >1 micro

23 Vasoactive intestinal peptide and its G protein-coupled

24 Vasoactive intestinal peptide and its G-protein-coupled

25 uced in these neurons after axotomy, such as vasoactive intestinal peptide and pituitary adenylate cy

26 In particular, the effects of vasoactive intestinal peptide and secretin on intra-acin

27 etion triggered by SubP was synergistic with vasoactive intestinal peptide and/or forskolin but not w

28 rosine kinase, endothelial progenitor cells, vasoactive intestinal peptide, and miRNA in PAH therapeu

29 sion of this isotype, including IL-10, IL-2, vasoactive intestinal peptide, and TGF-beta.

30 Muscarinic M2 receptors, nitric oxide and vasoactive intestinal peptide are inhibitory and regulat

31 ls did not colocalize with those against the vasoactive intestinal peptide-associated protein PHM27.

32 Secretomotor neurons, which release vasoactive intestinal peptide at their junctions with in

33 Vasoactive intestinal peptide binding to VPAC(2) on CD4

34 reverse transcription-PCR and (125)I-labeled vasoactive intestinal peptide binding, both IK-1 and IK-

35 nsmembrane receptors that includes secretin, vasoactive intestinal peptide, calcitonin, and corticotr

36 n mCry1 expression and its interactions with vasoactive intestinal peptide, cAMP, and PER at the hear

37 T)-expressing interneurons are a subclass of vasoactive intestinal peptide (ChAT-VIP) neurons of whic

38 neurons were labeled in parvalbumin-Cre and vasoactive intestinal peptide-Cre mice.

39 g, and stimulation of transcription from the vasoactive intestinal peptide cytokine-responsive elemen

40 Vasoactive intestinal peptide dose-dependently stimulate

41 as elevated, and the dose-response curve for vasoactive intestinal peptide-elicited cAMP accumulation

42 n (SS), neuropeptide Y, cholecystokinin, and vasoactive intestinal peptide exhibited clearly detectab

43 rents activates muscarinic receptors on both vasoactive intestinal peptide-expressing (VIP) and parva

44 The relative weight of vasoactive intestinal peptide-expressing (Vip) interneur

45 Recent work has suggested that vasoactive intestinal peptide-expressing (VIP) interneur

46 Vasoactive intestinal peptide-expressing (VIP) interneur

47 In addition, vasoactive intestinal peptide-expressing axonal plexuses

48 Vasoactive intestinal peptide-expressing inhibitory neur

49 Recent studies on vasoactive intestinal peptide-expressing inhibitory neur

50 Vasoactive intestinal peptide-expressing interneurons (V

51 Finally, vasoactive intestinal peptide-expressing interneurons pr

52 tional connectivity of pyramidal neurons and vasoactive intestinal peptide-expressing interneurons wi

53 enhancers selective for parvalbumin (PV) and vasoactive intestinal peptide-expressing interneurons.

54 Optogenetic inhibition of vasoactive intestinal peptide-expressing neurons did not

55 ed controls is correlated with the number of vasoactive intestinal peptide-expressing SCN neurons.

56 training, either directly or via inhibiting vasoactive-intestinal-peptide-expressing interneurons, p

57 equired to stimulate depolarization, whereas vasoactive intestinal peptide failed to evoke any respon

58 ing polypeptide (PACAP), a new member of the vasoactive intestinal peptide family expressed in embryo

59 COS-7 cells and increased ability to induce vasoactive intestinal peptide gene expression in IMR-32

60 Vasoactive intestinal peptide had no effect, and its ant

61 ibitory neurons that express parvalbumin and vasoactive intestinal peptide have mutually antagonistic

62 To date, two peptides, cholecystokinin and vasoactive intestinal peptide, have been localized to su

63 ns of adoptively transferred N-alpha-syn and vasoactive intestinal peptide immunocytes or natural Tre

64 The position of vasoactive intestinal peptide-immunoreactive fibers was

65 emistry revealed colocalization of sst2A and vasoactive intestinal peptide immunoreactivities in ente

66 ed to the diminished light-induced c-fos and vasoactive intestinal peptide in the suprachiasmatic nuc

67 noreactive for parvalbumin, somatostatin, or vasoactive intestinal peptide) in layer 2/3 of mouse vis

68 ted agonist (isoproterenol (isoprenaline) or vasoactive intestinal peptide) in the presence of HCO3-

69 In contrast, purified vasoactive intestinal peptide induced and natural Tregs

70 in a approximately 1.8-fold increase in the vasoactive intestinal peptide-induced activation of aden

71 We report that vasoactive intestinal peptide inhibits the proliferation

72 tide-ir (CGRP-ir) were virtually absent, but vasoactive intestinal peptide-ir (VIP-ir) nerves were pr

73 that of arginine-vasopressin-IR (AVP-IR) and vasoactive intestinal peptide-IR (VIP-IR), but not with

74 F-IR neurons in submucosal ganglia expressed vasoactive intestinal peptide-IR and were likely to be s

75 cal trials, this antiproliferative action of vasoactive intestinal peptide may offer a new and promis

76 nt of the core clock gene period, as well as vasoactive intestinal peptide, melatonin, and the cAMP/M

77 tric oxide, cyclooxygenase-2 metabolites and vasoactive intestinal peptide, might modulate neurovascu

78 a cells as LIF and CNTF, including increased vasoactive intestinal peptide mRNA, STAT3 dimerization,

79 ides neurotensin, somatostatin, motilin, and vasoactive intestinal peptide occur largely in the stoma

80 8-bromo-cyclic AMP, 8-pCPT-2'-O-Me-cAMP, and vasoactive intestinal peptide on amylase release by 60%

81 d by gp120 was prevented by cotreatment with vasoactive intestinal peptide or activity-dependent neur

82 glands fail to secrete mucus in response to vasoactive intestinal peptide or forskolin; the failure

83 In SCN lacking vasoactive intestinal peptide or its receptor, mCry1 exp

84 rtion of neurons that expressed substance P, vasoactive intestinal peptide or nitric oxide synthase a

85 Endogenous mediators, such as vasoactive intestinal peptide or prostaglandin E2 (PGE2)

86 ast, interneurons containing neuropeptide Y, vasoactive intestinal peptide, or the 5-hydroxytryptamin

87 decrease in neuronal nitric oxide synthase, vasoactive intestinal peptide, PACAP, and tyrosine hydro

88 neuron-specific enolase, gastrin, glucagon, vasoactive intestinal peptide, pancreatic polypeptide, a

89 ced increased expression of cholecystokinin, vasoactive intestinal peptide, peptide YY, and somatosta

90 tonin gene-related peptide, substance P, and vasoactive intestinal peptide peptidergic fibers, at two

91 such as MiaPaCa-2 that are negative for the vasoactive intestinal peptide/pituitary adenylate cyclas

92 The vasoactive intestinal peptide/pituitary adenylate cyclas

93 More input to vasoactive intestinal peptide-positive (VIP+) neurons th

94 n-positive, somatostatin-positive (SST+), or vasoactive intestinal peptide-positive (VIP+) neurons, t

95 uted preferentially to surround suppression, vasoactive intestinal peptide-positive interneurons were

96 s primarily signaled motor action (licking), vasoactive intestinal peptide-positive neurons responded

97 nregulation of bone morphogenetic protein 2, vasoactive intestinal peptide, preopro-urotensin II-rela

98 r with three multiple response elements, the vasoactive intestinal peptide promoter and a cAMP respon

99 ADM, CGRP, vasoactive intestinal peptide, prostaglandin E2, isoprot

100 ranscriptional repressor sequence of the rat vasoactive intestinal peptide receptor (VIPR) gene const

101 ografts were analyzed for expression of NTR, vasoactive intestinal peptide receptor (VIPR), substance

102 yndrome, exonic duplications in the gene for vasoactive intestinal peptide receptor 2 (VIPR2), and ex

103 duplications occurring within a single gene: vasoactive intestinal peptide receptor 2 (VIPR2).

104 hat, upon agonist stimulation, a GPCR called vasoactive intestinal peptide receptor 2 (VPAC2) is shed

105 Vasoactive intestinal peptide receptor 2 can elicit immu

106 olase, agonists of natriuretic peptide A and vasoactive intestinal peptide receptor 2, and a novel mi

107 located within 89 kilobases upstream of the vasoactive intestinal peptide receptor gene VIPR2.

108 aneous nerves and mRNA, for the VIP receptor vasoactive intestinal peptide receptor type 1, and vasoa

109 tive intestinal peptide receptor type 1, and vasoactive intestinal peptide receptor type 2 have been

110 tegration of stimulatory (Galpha(s)-mediated vasoactive intestinal peptide receptor) and inhibitory (

111 novel peptide with structural similarity to vasoactive intestinal peptide, regulates production of e

112 Among the vasoactive intestinal peptide/secretin/glucagon family o

113 NF145-IR was found in neurons with vasoactive intestinal peptide, serotonin, nitric oxide s

114 e product 9.5 (SGII[PGP9.5]) and peptidergic vasoactive intestinal peptide (SGII[VIP]), and cutaneous

115 These findings implicate altered vasoactive intestinal peptide signalling in the pathogen

116 cotropin-releasing hormone, neurotensin, and vasoactive intestinal peptide; small molecules include a

117 in number than either the cholecystokinin or vasoactive intestinal peptide subsets, overlapped 100% w

118 tters such as acetylcholine, norepinephrine, vasoactive intestinal peptide, substance P and histamine

119 9.5, neuronal nitric oxide synthase (nNOS), vasoactive intestinal peptide, substance P, and tyrosine

120 The strong secretory response to vasoactive intestinal peptide, the acidity of [cAMP](i)-

121 stem cells, we found that costimulation with vasoactive intestinal peptide (V) and phorbol ester (P)

122 onal relationship between cfos expression in vasoactive intestinal peptide (VIP) -containing neurons

123 ylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) activate two shared

124 Conversely, vasoactive intestinal peptide (VIP) activated GIRK chann

125 Vasoactive intestinal peptide (VIP) analog (TP3982) was

126 We find that vasoactive intestinal peptide (VIP) and a VPAC2 (VIP rec

127 ence experiments revealed that antibodies to vasoactive intestinal peptide (VIP) and calbindin-D28K (

128 used to determine the role of G proteins in vasoactive intestinal peptide (VIP) and carbachol-stimul

129 Vasoactive intestinal peptide (VIP) and corticotropin-re

130 Vasoactive intestinal peptide (VIP) and DAPTA (D-ala(1)-

131 e in response to inhibitory neurotransmitter vasoactive intestinal peptide (VIP) and direct electrica

132 spectum, are approximately 50% homologous to vasoactive intestinal peptide (VIP) and glucagon-like pe

133 opic double labeling immunocytochemistry for vasoactive intestinal peptide (VIP) and gonadotrophin-re

134 diated by the primary coupling neuropeptide, vasoactive intestinal peptide (VIP) and its canonical re

135 The vasoactive intestinal peptide (VIP) and its G protein-co

136 Vasoactive intestinal peptide (VIP) and its G protein-co

137 Vasoactive intestinal peptide (VIP) and its G-protein-co

138 (SCG) dramatically increase their content of vasoactive intestinal peptide (VIP) and its mRNA after a

139 Vasoactive intestinal peptide (VIP) and its two G protei

140 HMG) cells were examined for the presence of vasoactive intestinal peptide (VIP) and muscarinic acety

141 The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenyl

142 The effects of vasoactive intestinal peptide (VIP) and pituitary adenyl

143 Neuropeptides such as the vasoactive intestinal peptide (VIP) and pituitary adenyl

144 Vasoactive intestinal peptide (VIP) and pituitary adenyl

145 Neuropeptides such as vasoactive intestinal peptide (VIP) and pituitary adenyl

146 The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenyl

147 The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenyl

148 We reported recently that the neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenyl

149 Vasoactive intestinal peptide (VIP) and pituitary adenyl

150 activity in the visual cortex contains both vasoactive intestinal peptide (VIP) and somatostatin (SS

151 o known immunosuppressive neuropeptides, the vasoactive intestinal peptide (VIP) and the pituitary ad

152 The vasoactive intestinal peptide (VIP) and the pituitary ad

153 Vasoactive intestinal peptide (VIP) and the pituitary ad

154 e of two immunomodulatory neuropeptides, the vasoactive intestinal peptide (VIP) and the pituitary ad

155 two structurally related neuropeptides, the vasoactive intestinal peptide (VIP) and the pituitary ad

156 Because the neuropeptide vasoactive intestinal peptide (VIP) and the structurally

157 Vasoactive intestinal peptide (VIP) and the structurally

158 The vasoactive intestinal peptide (VIP) and the structurally

159 Using antibodies directed against vasoactive intestinal peptide (VIP) and tyrosine hydroxy

160 /c mice were injected intraperitoneally with vasoactive intestinal peptide (VIP) antagonist and simil

161 Vasoactive intestinal peptide (VIP) appears to be respon

162 e cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are implicated in th

163 Although VPAC1 and its ligand vasoactive intestinal peptide (VIP) are important in gas

164 e cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) are related neuropep

165 Immune cellular effects of vasoactive intestinal peptide (VIP) are transduced by VI

166 concentration efficiency for the target drug vasoactive intestinal peptide (VIP) as conventional part

167 s from our laboratory have demonstrated that vasoactive intestinal peptide (VIP) directly converts th

168 Exogenous vasoactive intestinal peptide (VIP) down-regulates pro-i

169 In contrast a peptide related to PACAP, vasoactive intestinal peptide (VIP) failed to induce CRE

170 ylate cyclase-activating polypeptide (PACAP)/vasoactive intestinal peptide (VIP) family of peptides m

171 l with muscarinic agonists, substance P, and vasoactive intestinal peptide (VIP) functioning as effec

172 Vasoactive intestinal peptide (VIP) gene expression is h

173 induction of expression of the neuropeptide vasoactive intestinal peptide (VIP) gene is mediated by

174 ceptor subunit activate transcription of the vasoactive intestinal peptide (VIP) gene through a 180 b

175 (TGF-beta) both induce transcription of the vasoactive intestinal peptide (VIP) gene through a 180-b

176 (CNTF) potently induces transcription of the vasoactive intestinal peptide (VIP) gene through a 180-b

177 Vasoactive intestinal peptide (VIP) has a high affinity

178 Vasoactive intestinal peptide (VIP) has a role in immuno

179 The neuropeptide vasoactive intestinal peptide (VIP) has also been found

180 Vasoactive intestinal peptide (VIP) has been found to re

181 The neuropeptide vasoactive intestinal peptide (VIP) has been shown to in

182 Vasoactive intestinal peptide (VIP) has been widely acce

183 Vasoactive intestinal peptide (VIP) has potent antiproli

184 Drosophila is remarkably similar to that of vasoactive intestinal peptide (VIP) in mammals.

185 The prominence of vasoactive intestinal peptide (VIP) in rodent thymic neu

186 a representative type of non-opioid peptides vasoactive intestinal peptide (VIP) in the amygdala to m

187 small proline-rich protein 1a (sprr1a), and vasoactive intestinal peptide (vip) in the trigeminal ga

188 Vasoactive intestinal peptide (VIP) induced REMS respons

189 Vasoactive intestinal peptide (VIP) induces regulatory d

190 Vasoactive intestinal peptide (VIP) induces Th2 response

191 ubpopulations containing parvalbumin (PV) or vasoactive intestinal peptide (VIP) innervate distinct p

192 t principal excitatory (EXC) neurons and the vasoactive intestinal peptide (VIP) interneurons that su

193 One solution to this problem could be the vasoactive intestinal peptide (VIP) interneurons, which

194 Vasoactive intestinal peptide (VIP) is a naturally occur

195 Vasoactive intestinal peptide (VIP) is a neuroendocrine

196 Vasoactive intestinal peptide (VIP) is a neuromediator e

197 Vasoactive intestinal peptide (VIP) is a neuromodulator

198 Vasoactive intestinal peptide (VIP) is a neuropeptide wi

199 Vasoactive intestinal peptide (VIP) is a neurotransmitte

200 Vasoactive intestinal peptide (VIP) is a pleiotropic neu

201 Vasoactive intestinal peptide (VIP) is a potent immunomo

202 Vasoactive intestinal peptide (VIP) is an acknowledged n

203 Vasoactive intestinal peptide (VIP) is an anti-inflammat

204 Vasoactive intestinal peptide (VIP) is an anti-inflammat

205 Vasoactive intestinal peptide (VIP) is expressed by corn

206 Vasoactive intestinal peptide (VIP) is more prominent in

207 Cells that express the neuropeptide vasoactive intestinal peptide (VIP) mediate retinal entr

208 Vasoactive intestinal peptide (VIP) mediates a broad ran

209 Vasoactive intestinal peptide (VIP) modulates immune res

210 R IR occurs exclusively in 50% of submucosal vasoactive intestinal peptide (VIP) neurons (interneuron

211 faceted approach in mice, we have identified vasoactive intestinal peptide (VIP) neurons as a novel c

212 ed by sound, while visual responses of L2/L3 vasoactive intestinal peptide (VIP) neurons were suppres

213 n interneurons expressing Cre recombinase in vasoactive intestinal peptide (VIP) or parvalbumin (PV)

214 synthase (NOS), serotonin, substance P (SP), vasoactive intestinal peptide (VIP) or vesicular acetylc

215 To determine whether vasoactive intestinal peptide (VIP) played a role in dev

216 hormone (GHRH) can potentially interact with vasoactive intestinal peptide (VIP) receptors (VPAC(1)-R

217 tested the hypothesis that the neuropeptide vasoactive intestinal peptide (VIP) regulates adhesion m

218 Vasoactive intestinal peptide (VIP) released from some n

219 cell line NBFL increased CNTF induction of a vasoactive intestinal peptide (VIP) reporter gene, and i

220 We show that vasoactive intestinal peptide (VIP) secreted by the inne

221 ntaining choline acetyltransferase (ChAT) or vasoactive intestinal peptide (VIP) share characteristic

222 ng parvalbumin (PV), somatostatin (SST), and vasoactive intestinal peptide (VIP) show cell-type-speci

223 demonstrated their dependence upon G-coupled vasoactive intestinal peptide (VIP) signaling.

224 cyclase-activating polypeptide (PACAP), and vasoactive intestinal peptide (VIP) suppress Langerhans

225 Vasoactive intestinal peptide (VIP) suppresses Th1 immun

226 The potent PACAP/vasoactive intestinal peptide (VIP) type I receptor anta

227 decreased the area of nitrergic neurons and vasoactive intestinal peptide (VIP) varicosities.

228 The immunoregulatory neuropeptide vasoactive intestinal peptide (VIP) was cleaved by purif

229 mpartment where the 5-HT4 agonist was added; vasoactive intestinal peptide (VIP) was released only in

230 Vasoactive intestinal peptide (VIP) was shown to be prod

231 s calcitonin gene-related peptide (CGRP) and vasoactive intestinal peptide (VIP) were potent but less

232 a population of enteric neurons that express vasoactive intestinal peptide (VIP)(4).

233 rpose of this study was to determine whether vasoactive intestinal peptide (VIP), a 28-amino acid neu

234 Vasoactive intestinal peptide (VIP), a neuropeptide pres

235 It closely resembles vasoactive intestinal peptide (VIP), a neuropeptide well

236 Vasoactive intestinal peptide (VIP), a neuropeptide with

237 Vasoactive intestinal peptide (VIP), a neuropeptide, may

238 Vasoactive intestinal peptide (VIP), a pulmonary vasodil

239 Vasoactive Intestinal Peptide (VIP), a pulmonary vasodil

240 .5 (PGP 9.5), a general neuronal marker, and vasoactive intestinal peptide (VIP), a sudomotor nerve f

241 cocultured with different concentrations of vasoactive intestinal peptide (VIP), adult rat RPE cells

242 T2) to model HCMV reactivation, we show that vasoactive intestinal peptide (VIP), an immunomodulatory

243 sion of the anti-inflammatory neuropeptides, vasoactive intestinal peptide (VIP), and pituitary adeny

244 G) dramatically increases levels of galanin, vasoactive intestinal peptide (VIP), and substance P and

245 holinergic and alpha(1)-adrenergic agonists, vasoactive intestinal peptide (VIP), and the purinergic

246 against protein gene product (PGP)-9.5, SP, vasoactive intestinal peptide (VIP), and tyrosine hydrox

247 opulations, expressing somatostatin (SOM) or vasoactive intestinal peptide (VIP), are active as popul

248 es (Abs) to an autoantigen, the neuropeptide vasoactive intestinal peptide (VIP), by a covalently rea

249 ons processed for tyrosine hydroxylase (TH), vasoactive intestinal peptide (VIP), calcitonin gene-rel

250 neuronal markers including parvalbumin (PV), vasoactive intestinal peptide (VIP), calretinin, calbind

251 than 90% of neuronal nitric oxide synthase, vasoactive intestinal peptide (VIP), calretinin, or neur

252 d by silver-gold enhancement of staining for vasoactive intestinal peptide (VIP), cholecystokinin (CC

253 We explored the relation between vasoactive intestinal peptide (VIP), CRTH2, and eosinoph

254 t their regulation by neuropeptides, such as vasoactive intestinal peptide (VIP), during Pseudomonas

255 Vasoactive intestinal peptide (VIP), forskolin, and geni

256 iety of transmitters including nitric oxide, vasoactive intestinal peptide (VIP), gastrin-releasing p

257 essing parvalbumin (PV), somatostatin (SOM), vasoactive intestinal peptide (VIP), or neuropeptide Y.

258 of neuropeptides of the family that includes vasoactive intestinal peptide (VIP), peptide histidine i

259 measure the neuropeptides substance P (SP), vasoactive intestinal peptide (VIP), pituitary adenylate

260 The major 28-aa neuropeptide, vasoactive intestinal peptide (VIP), provides neuroprote

261 ntal Cell, Nedvetsky et al. (2014) find that vasoactive intestinal peptide (VIP), secreted by parasym

262 al that locomotion increases the activity of vasoactive intestinal peptide (VIP), somatostatin (SST)

263 ma-aminobutyric acidergic neurons expressing vasoactive intestinal peptide (Vip), somatostatin (Sst),

264 Antibodies to vasoactive intestinal peptide (VIP), tyrosine hydroxylas

265 ne-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP), tyrosine hydroxylas

266 ctionally important neuropeptides, including vasoactive intestinal peptide (VIP), which drives light

267 geted to the inhibitory synapses made by the vasoactive intestinal peptide (VIP)- and calretinin-posi

268 ow that disinhibitory circuits consisting of vasoactive intestinal peptide (VIP)-expressing and somat

269 uble-label immunocytochemistry revealed that vasoactive intestinal peptide (VIP)-expressing cells, bu

270 Parvalbumin (PV)- and Vasoactive intestinal peptide (VIP)-expressing INs exhib

271 owever, targeting of somatostatin (SOM)- and vasoactive intestinal peptide (VIP)-expressing INs led t

272 tional ErbB4 deletion, we tested the role of vasoactive intestinal peptide (VIP)-expressing interneur

273 to light induces a gene program in cortical vasoactive intestinal peptide (VIP)-expressing neurons t

274 cuit inhibition and a subsequent increase in vasoactive intestinal peptide (VIP)-mediated disinhibiti

275 In contrast, activating vasoactive intestinal peptide (VIP)-positive interneuron

276 g animals revealed that locomotion activates vasoactive intestinal peptide (VIP)-positive neurons in

277 sitive and calretinin (Cr)-positive (but not vasoactive intestinal peptide (VIP)-positive) interneuro

278 inding of (125)I-JV-1-42 is not inhibited by vasoactive intestinal peptide (VIP)-related peptides sha

279 face (ALI) vs submerged] and the presence of vasoactive intestinal peptide (VIP).

280 litude of pacemaking in SCN circuits lacking vasoactive intestinal peptide (VIP).

281 appaB does not confer MIE gene activation by vasoactive intestinal peptide (VIP).

282 ption, including glucagon-like peptide 1 and vasoactive intestinal peptide (VIP).

283 in response to both acetylcholine (ACh) and vasoactive intestinal peptide (VIP).

284 carbon monoxide (CO), nitric oxide (NO), and vasoactive intestinal peptide (VIP).

285 and negative for parvalbumin (PV) as well as vasoactive intestinal peptide (VIP).

286 nd shares two receptors VPAC1 and VPAC2 with vasoactive intestinal peptide (VIP).

287 tinorecipient cells that express and release vasoactive intestinal peptide (VIP).

288 sses from noradrenaline to acetylcholine and vasoactive intestinal peptide (VIP).

289 PEG5kDa-cholane) to a 28 amino acid peptide, vasoactive intestinal peptide (VIP).

290 ctly on nociceptors to induce the release of vasoactive intestinal peptide (VIP).

291 -Rs) with the selective agonist maxadilan or vasoactive intestinal peptide (VIP)/PACAP (VPAC) recepto

292 originating from the SCN neurons expressing vasoactive intestinal peptide (VIP+ neurons).

293 ic factor (NDNF+) cells in L1a and MD drives vasoactive intestinal peptide (VIP+) cells in L1b.

294 ass of interneurons in DS - those expressing vasoactive intestinal peptide (VIP-IN) -is unknown.

295 ments of synaptic activity in populations of vasoactive-intestinal peptide (VIP) interneurons express

296 Epithelial responsiveness to vasoactive intestinal peptide was increased after enteri

297 of parvalbumin (PV), somatostatin (SST), and vasoactive intestinal peptide were decreased in hypoxic-

298 mmunohistochemistry demonstrated that TH and vasoactive intestinal peptide were detectable at P14 and

299 ioactive peptides, angiotensins I and II and vasoactive intestinal peptide, were also hydrolyzed rapi

300 for vesicular acetylcholine transporter and vasoactive intestinal peptide when they reached the ster